1European Society of Hypertension - European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - E - uropean society of Cardiology guidelines for the management of arterial hypertension [ J ]. Hypertens, 2003,21 : 1011 - 1053.
2CHOBANIAN A V, BAKRIS G L, BLACK H B, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA ,2003,289:2560 - 2572.
3FENICHEL R R, LIPICKY R J. Combination products as flint - line pha - rmacotherapy[ J ]. Arch Intern Med, 1994,154 : 1429 - 1430.
4Qin XP,Ye F,Liao DF,et al. Involvement of calciton in generelated peptide in depressor effects of losartan and perindopril in rats [J]. Eur J Pharmaeol, 2003,464 ( 1 ) : 63-67.
5Uzu T,Nishimura M,Fujii T,et al. Benidipine attenuates glomerruler hypertension and reduces albuminuria in patients with metabolic syn- drome [J]. Hypertens Res, 2007,30 : 161-165.
6Akizuki O,lnayoshi A,Kitayama T,et al. Blockade of T-type voltage-dependent Ca2+ channels by benidipine A dihydropyridine calcium chan- nel blocker,inhibits aldosterone production in human adrenocortical cell line NCI-H295 R [J]. Eur J Pharmacol, 2008,584 : 424-434.
7Saito F,Fujita H,Takahashi A,et al. Renoprotective effect and cost-ef- fectiveness of using benidipine,a calcium channel blocker,to lower the dose of angiotensin receptor blocker in hypertensive patients with albu- minuria [J]. Hylxntens Res, 2007,30 : 39-47.
8Hayashi K,Wakino S,Homma K,et al. Pathophysiological significance of T-type Ca2+ channel:role of T-type Ca2+ channel in renal microcircu- lation [J]..l Pharmacol Sci ,2005,99:221-227.
9Gashti CN, Bakris GL. The role of calcium antagonists in chronic kidney disease [J]. Curr Opin Nephrol Hypertens,2004,13:155-161.
10Matsuzaki G,Ishizaka N ,Furuta K,et al. Comparison of vasculoprotec-tive effects of benidipine and losartan in a rat model of metabolic syn- drome [J]. Eur J Pharmaeol,2008,587:237-242,.
